- $50.55m
- $34.67m
- $0.78m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 65.21 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -4641.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.02 | 0.01 | 0.09 | 0.31 | 0.78 | 3.63 | 15.59 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Directors
- Martin Faulkes CHM (77)
- Cameron Reynolds CEO (50)
- Terig Hughes CFO (51)
- Salvatore Butera CEX (70)
- Jasmine Kway CEX (49)
- Jacob Micallef CSO (64)
- Gael Forterre OTH (40)
- Jason Terrell OTH (40)
- Rodney Rootsaert SEC (49)
- Phillip Barnes IND (59)
- Richard Brudnick IND (64)
- Alan Colman IND (72)
- Edward Futcher IND (66)
- Guy Innes IND (64)
- Kim Nguyen IND (44)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 24th, 1998
- Public Since
- February 6th, 2015
- No. of Shareholders
- 160
- No. of Employees
- 110
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NYSE MKT- Shares in Issue
- 82,068,442
- Address
- 1489 West Warm Springs Road, Suite 110, HENDERSON, 89014
- Web
- https://volition.com/
- Phone
- +1 6466501351
- Contact
- Scott Powell
- Auditors
- Sadler, Gibb & Associates, LLC
Upcoming Events for VNRX
VolitionRX Ltd Annual Shareholders Meeting
Q2 2024 VolitionRX Ltd Earnings Release
Similar to VNRX
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
AIM ImmunoTech
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
Azitra
NYSE MKT
FAQ
What is the VolitionRX share price?
As of Today at 19:24 UTC, shares in VolitionRX are trading at $0.62. This share price information is delayed by 15 minutes.
How has the VolitionRX share price performed this year?
Shares in VolitionRX last closed at $0.62 and the price had moved by -63.76% over the past 365 days. In terms of relative price strength the VolitionRX share price has underperformed the S&P500 Index by -69.85% over the past year.
What are the analyst and broker recommendations for VolitionRX?
The overall consensus recommendation for VolitionRX is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the VolitionRX dividend yield?
VolitionRX does not currently pay a dividend.
Does VolitionRX pay a dividend?
VolitionRX does not currently pay a dividend.
When does VolitionRX next pay dividends?
VolitionRX does not currently pay a dividend.
How do I buy VolitionRX shares?
To buy shares in VolitionRX you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of VolitionRX?
As of the previous close price of $0.62, shares in VolitionRX had a market capitalisation of $50.55m.
Where are VolitionRX shares listed?
Here are the trading details for VolitionRX:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: VNRX
What kind of share is VolitionRX?
Based on an overall assessment of its quality, value and momentum VolitionRX is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a VolitionRX share price forecast for 2024?
The analyst consensus target price for shares in VolitionRX is $3.73. That is 505.52% above the last closing price of $0.62.
Analysts covering VolitionRX currently have a consensus Earnings Per Share (EPS) forecast of -$0.41 for the next financial year.
What is the trend in the VolitionRX share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like VolitionRX. Over the past six months, its share price has underperformed the S&P500 Index by -32.71%.
As of the last closing price of $0.62, shares in VolitionRX were trading -35.72% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the VolitionRX PE Ratio?
The VolitionRX PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.62.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of VolitionRX?
VolitionRX's management team is headed by:
- Martin Faulkes - CHM
- Cameron Reynolds - CEO
- Terig Hughes - CFO
- Salvatore Butera - CEX
- Jasmine Kway - CEX
- Jacob Micallef - CSO
- Gael Forterre - OTH
- Jason Terrell - OTH
- Rodney Rootsaert - SEC
- Phillip Barnes - IND
- Richard Brudnick - IND
- Alan Colman - IND
- Edward Futcher - IND
- Guy Innes - IND
- Kim Nguyen - IND